FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a T-cell or NK-cell, which includes a CAR molecule, which contains a first CAR that binds to BCMA (BCMA CAR), a second CAR that binds to CD19 (CD19 CAR), to a composition containing it, as well as to an isolated nucleic acid molecule coding a chimeric antigen receptor (CAR) molecule, where said nucleic acid molecule comprises a first nucleic acid sequence coding a first CAR that binds to BCMA (BCMA CAR), a second nucleic acid sequence coding a second CAR which binds to CD19 (CD19 CAR), and an isolated CAR molecule which binds to BCMA and CD19. Also disclosed is a vector, a cell containing said nucleic acid molecule, as well as a method of producing said cell. Invention also relates to a population of T-cells or NK-cells for expression of the CAR molecule.
EFFECT: invention is effective for providing anti-tumour immunity in a subject.
22 cl, 33 dwg, 34 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| METHODS OF PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2019 |
|
RU2822196C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| COMPOSITIONS AND METHODS OF SELECTIVE PROTEIN DEGRADATION | 2018 |
|
RU2811700C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| TREATING CANCER USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANIZED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2831418C2 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
